23 October 2020 - The Institute for Cancer Research has called for change in the way immunotherapy drugs are researched and evaluated after the NICE handed MSD’s Keytruda plus chemotherapy a rejection.

Although NICE reversed a draft rejection of Keytruda (pembrolizumab) and has now recommended it for use on the NHS as a first-line treatment for head and neck cancer in PD-L1-positive patients, ICR is ‘disappointed’ that a combination of Keytruda plus chemotherapy combination was not also approved.

Read Pharma Times article